What was the Market Segmentation of the Multiple Sclerosis Drugs Market?

By Type (Immunomodulators, Interferons, Immunosuppressants, and Others), Route of Administration (Oral, Parenteral, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Others)

What is the CAGR of Multiple Sclerosis Drugs Market?

The Multiple Sclerosis Drugs Marketis growing at a CAGR of 3.8% during the forecast period 2023 to 2033.

Who are the major players operating in the Multiple Sclerosis Drugs Market?

Celgene Corporation, Abbvie Inc., Acorda Therapeutics Inc., Actelion Pharmaceuticals (Johnson & Johnson), Adamas Pharmaceuticals Inc, Bayer AG, Biogen Inc., Cipla Inc., Eli Lilly and Company, EMD Serono (Merck KGaA), Pfizer Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Novartis AG., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Other Key Players

Which region will lead the Global Multiple Sclerosis Drugs Market?

North America is estimated to be the fastest-growing region during the forthcoming years.

Global Multiple Sclerosis Drugs Market By Type (Immunomodulators, Interferons, Immunosuppressants), Route Of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Online Pharmacy) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032

Published date: Nov 2023
Report ID: 51496
Number of Pages: 215
Format:

- Celgene Corporation
- AbbVie Inc. Company Profile
- Acorda Therapeutics Inc.
- Actelion Pharmaceuticals (Johnson & Johnson)
- Adamas Pharmaceuticals Inc
- Bayer AG Company Profile
- Biogen Inc.
- Cipla Inc.
- Eli Lilly and Company
- EMD Serono (Merck KGaA)
- Pfizer Inc Company Profile
- Sanofi Company Profile
- Teva Pharmaceuticals Industries Ltd.
- Novartis AG.
- Bristol-Myers Squibb Company
- Hoffmann-La Roche Ltd.
- Other Key Players

Related Reports

Our Clients

Report ID 51496
Published Date Nov 2023
Rating
- ★★★★★
  
  ★★★★★
- (27)

Buy Now

Trusted by more than 17382 organizations globally

✖

Request a Sample Report

We'll get back to you as quickly as possible